Clinical Papers & Articles

GLAUCOMA

Selective Laser Trabeculoplasty vs Micropulse Laser Trabeculoplasty for the Treatment of Open Angle Glaucoma and Ocular Hypertension
Dr. Marcela Irene De Leon De Leon, Dr. Jose Francisco Ortega Santana, Dr. Alfonso Garcia Lopez
International Journal of Research in Medical and Health Sciences
February 2017, Vol 14, No 01-2017


Abstract:
Controlled, prospective, longitudinal, clinical trial with the objective to compare the efficacy of the micropulse laser trabeculoplasty (MLT) and the selective laser trabeculoplasty (SLT) in patients with open angle glaucoma or ocular hypertension. Patients were divided into two groups depending on the laser procedure, the group 1 was treated with SLT and the group 2 was treated with MLT; then they were followed for 3 months. 67 eyes were included in the trial (SLT: 38 eyes of 24 patients and MLT: 29 eyes of 19 patients). The average of age of the patients treated with SLT was 68.4 ± 8.8 years and with MLT 77.7 ± 7.3 years. The previous IOP was similar in both groups (SLT: 19.53 ± 4.03 mmHg, MLT: 19.76 ± 4.23 mmHg), a week after treatment (SLT: 18.53 ± 4.08 mmHg, MLT: 17.14 ± 5.19 mmHg), at month (SLT: 14.79 ± 2.42 mmHg, MLT: 16.26 ± 3.39 mmHg) and at 3 months (SLT: 15.66 ± 2.48 mmHg, MLT: 15.83 ± 3.19 mmHg). The percentage of IOP reduction was 19.81% with SLT and 19.89% with MLT. There was no statistically significant difference between the average IOP of both groups over 3 months of follow up. There was no difference in the number of drugs previous and posterior to the procedures, and there was not observed complications at any of the groups. The IOP-lowering effect of SLT and MLT was similar over 3 months in this group of patients and both proved to be safe procedures. 

Products Featured: LIGHTLas SLT Deux, TruScan 577 with SP-Mode


RETINA

Jamshed Ahmed, Rommana Fasih
Journal of Pakistan Medical Association
May 2016, Vol 66, No 5

Abstract
Objective: To determine the anatomical and functional improvement in eyes with diffuse macular oedema after modified mild macular grid laser.

Methods: The prospective study was conducted at the Department of Ophthalmology Unit II, Civil Hospital Karachi, and the Department of Ophthalmology, Dow International Medical College, Karachi, from June 2011 to May 2014. We used neodymium-doped yttrium aluminium garnet 532nm frequency-doubled green laser to treat all eligible patients. Treatment variables were a spot size of 50 microns, exposure duration of 0.1 seconds, and power sufficient to produce barely visible burns in a grid pattern. We treated the thickened retina and non-thickened area of the macula excluding central 500 micron. Microaneurysms within the macular areas were treated by focal application of laser shots sufficient to bleach them.

Results: The study comprised 86 eyes of 52 patients who were treated by applying 180 to 360 burns with a mean of 275±51. Mean macular thickness differed significantly between time points (Wilks' Lambda 0.139; F (2, 6) = 125.95; p = 0.00001). Mean visual acuity changed significantly between time points (Wilks' Lambda 0.535; F (4, 82) = 17.8; p = 0.00001). At the last follow-up, visual acuity improved at least one line in 32(37.2%) eyes, remained stable in 48(55.8%) eyes, and declined in 6(6.9%) eyes.

Conclusion: Modified mild macular grid is an effective and safe procedure for patients with diffuse diabetic macular oedema.

Products Featured: LIGHTLas YAG/532 Combo System with SP-Mode


Dr. Igor Remesnikov
Astana Vision, Astana City, Republic of Kazakhstan
 
Products Featured: LIGHTLas YAG/577 Combo System with SP-Mode

VITREOLYSIS

Dixie Ophthalmic Specialists at Zion Eye Institute 
Article courtesy of The Spectrum
Author: Nichole Osinski
April 2016
 
Products Featured: LIGHTLas SLT Deux + Vitreolysis